Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Inotersen - Akcea Therapeutics/Ionis Pharmaceuticals

Next Previous
Search
Drug Profile

Inotersen - Akcea Therapeutics/Ionis Pharmaceuticals

Alternative Names: GSK 2998728; Human transthyretin antisense oligonucleotide - Akcea Therapeutics/Ionis Pharmaceuticals; Inotersen; Inotersen sodium - Akcea Therapeutics/Ionis Pharmaceuticals; IONIS-TTRRx; ISIS 420915 salt; ISIS-420915; ISIS-GSK1Rx; ISIS-TTRRx; Phosphorothioate oligonucleotide - Akcea Therapeutics/Ionis Pharmaceuticals; TEGSEDI

Latest Information Update: 05 Nov 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Isis Pharmaceuticals
  • Developer Akcea Therapeutics; GSK; Indiana University School of Medicine; Ionis Pharmaceuticals; PTC Therapeutics
  • Class Antisense oligonucleotides; Cardiovascular therapies; Neuroprotectants
  • Mechanism of Action Prealbumin expression inhibitors; RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Amyloid polyneuropathy
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Amyloid polyneuropathy
  • Phase II Amyloidosis; Cardiomyopathies

Most Recent Events

  • 07 Jan 2021 Isis Pharmaceuticals completes the phase III NEURO-TTR trial for Amyloid polyneuropathy in USA, United Kingdom, France, Argentina, Brazil, Portugal, Italy, Spain and Germany (NCT02175004)
  • 12 Oct 2020 Akcea Therapeutics has been acquired by Ionis Pharmaceuticals
  • 05 Aug 2020 Ionis Pharmaceuticals plans to launch Inotersen for Amyloid polyneuropathy in additional EU countries and in Latin America, in 2020

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top